(ACHC) Acadia Healthcare - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 2.117m USD | Total Return: -0.1% in 12m

Psychiatric Hospitals, Treatment Centers, Outpatient Care
Total Rating 34
Safety 37
Buy Signal -0.06
Medical Care Facilities
Industry Rotation: +6.5
Market Cap: 2.12B
Avg Turnover: 69.1M
Risk 3d forecast
Volatility65.5%
VaR 5th Pctl10.0%
VaR vs Median-8.90%
Reward TTM
Sharpe Ratio0.32
Rel. Str. IBD54.2
Rel. Str. Peer Group69.4
Character TTM
Beta0.872
Beta Downside0.875
Hurst Exponent0.530
Drawdowns 3y
Max DD86.63%
CAGR/Max DD-0.35
CAGR/Mean DD-0.72
EPS (Earnings per Share) EPS (Earnings per Share) of ACHC over the last years for every Quarter: "2021-03": 0.47, "2021-06": 0.71, "2021-09": 0.72, "2021-12": 0.67, "2022-03": 0.67, "2022-06": 0.84, "2022-09": 1.64, "2022-12": 0.7, "2023-03": 0.75, "2023-06": 0.92, "2023-09": 0.91, "2023-12": 0.85, "2024-03": 0.84, "2024-06": 0.91, "2024-09": 0.91, "2024-12": 0.64, "2025-03": 0.4, "2025-06": 0.83, "2025-09": 0.72, "2025-12": 0.07, "2026-03": 0.37,
EPS CAGR: -19.93%
EPS Trend: -89.7%
Last SUE: 1.87
Qual. Beats: 1
Revenue Revenue of ACHC over the last years for every Quarter: 2021-03: 551.199, 2021-06: 582.156, 2021-09: 587.559, 2021-12: 593.48, 2022-03: 616.653, 2022-06: 651.719, 2022-09: 666.732, 2022-12: 675.295, 2023-03: 704.267, 2023-06: 731.337, 2023-09: 750.334, 2023-12: 742.8, 2024-03: 768.051, 2024-06: 796.04, 2024-09: 815.634, 2024-12: 774.238, 2025-03: 770.505, 2025-06: 869.232, 2025-09: 851.573, 2025-12: 821.459, 2026-03: 828.802,
Rev. CAGR: 6.79%
Rev. Trend: 98.7%
Last SUE: 0.39
Qual. Beats: 0

Warnings

Interest Coverage Ratio -6.0 is critical

Altman Z'' -1.29 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: ACHC Acadia Healthcare

Acadia Healthcare Company, Inc. (ACHC) is a provider of behavioral healthcare services operating across the United States and Puerto Rico. Established in 2005 and headquartered in Franklin, Tennessee, the company manages a diverse network of facilities including acute inpatient psychiatric hospitals, residential recovery centers, and comprehensive treatment centers for eating disorders and substance abuse.

The behavioral health sector is characterized by high barriers to entry due to stringent state certificate-of-need regulations and specialized staffing requirements. Acadia utilizes a hub-and-spoke business model, integrating intensive inpatient care with outpatient behavioral health services to capture the full continuum of patient recovery needs.

Investors can evaluate the company’s facility utilization rates and expansion pipeline by reviewing the latest data on ValueRay. This specialized healthcare segment often experiences counter-cyclical demand patterns as mental health services remain a critical medical necessity regardless of broader economic conditions.

Headlines to Watch Out For
  • DOJ investigation into patient safety and billing practices increases legal liability risks
  • Bed capacity expansion and facility acquisitions drive core inpatient revenue growth
  • Tight labor market for specialized psychiatric nursing impacts operating margins
  • Rising demand for opioid use disorder treatment boosts outpatient center volume
  • Strategic joint ventures with nonprofit health systems expand market share reach
Piotroski VR-10 (Strict) 4.5
Net Income: -1.11b TTM > 0 and > 6% of Revenue
FCF/TA: -0.05 > 0.02 and ΔFCF/TA -1.03 > 1.0
NWC/Revenue: 10.32% < 20% (prev 5.25%; Δ 5.07% < -1%)
CFO/TA 0.03 > 3% & CFO 182.0m > Net Income -1.11b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.71 > 1.5 & < 3
Outstanding Shares: last quarter (90.9m) vs 12m ago -1.28% < -2%
Gross Margin: 56.21% > 18% (prev 0.63%; Δ 5.56k% > 0.5%)
Asset Turnover: 57.65% > 50% (prev 51.34%; Δ 6.31% > 0%)
Interest Coverage Ratio: -5.99 > 6 (EBITDA TTM -691.2m / Interest Expense TTM 148.0m)
Altman Z'' -1.29
A: 0.06 (Total Current Assets 837.2m - Total Current Liabilities 489.4m) / Total Assets 5.55b
B: -0.14 (Retained Earnings -761.7m / Total Assets 5.55b)
C: -0.15 (EBIT TTM -885.9m / Avg Total Assets 5.85b)
D: -0.23 (Book Value of Equity -760.8m / Total Liabilities 3.38b)
Altman-Z'' = -1.29 = CCC
Beneish M -3.23
DSRI: 1.10 (Receivables 547.7m/468.0m, Revenue 3.37b/3.16b)
GMI: 1.11 (GM 56.21% / 62.53%)
AQI: 0.67 (AQ_t 0.27 / AQ_t-1 0.40)
SGI: 1.07 (Revenue 3.37b / 3.16b)
TATA: -0.23 (NI -1.11b - CFO 182.0m) / TA 5.55b)
Beneish M = -3.23 (Cap -4..+1) = AA
What is the price of ACHC shares?

As of May 27, 2026, the stock is trading at USD 23.49 with a total of 2,367,062 shares traded.
Over the past week, the price has changed by -7.19%, over one month by -16.55%, over three months by +5.38% and over the past year by -0.13%.

Is ACHC a buy, sell or hold?

Acadia Healthcare has received a consensus analysts rating of 3.86. Therefore, it is recommended to buy ACHC.

  • StrongBuy: 6
  • Buy: 1
  • Hold: 6
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the ACHC price?
Analysts Target Price 28.3 20.3%
Acadia Healthcare (ACHC) - Fundamental Data Overview as of 23 May 2026
Market Cap USD = 2.12b (2.12b USD * 1.0 USD.USD)
P/E Forward = 16.0514
P/S = 0.628
P/B = 1.1299
P/EG = 1.3745
Revenue TTM = 3.37b USD
EBIT TTM = -885.9m USD
EBITDA TTM = -691.2m USD
Long Term Debt = 2.49b USD (from longTermDebt, last quarter)
Short Term Debt = 54.3m USD (from shortTermDebt, last quarter)
Debt = 2.81b USD (from shortLongTermDebtTotal, last quarter) + Leases 143.2m
Net Debt = 2.65b USD (calculated: Debt 2.81b - CCE 158.5m)
Enterprise Value = 4.77b USD (2.12b + Debt 2.81b - CCE 158.5m)
Interest Coverage Ratio = -5.99 (Ebit TTM -885.9m / Interest Expense TTM 148.0m)
EV/FCF = -16.35x (Enterprise Value 4.77b / FCF TTM -291.8m)
FCF Yield = -6.11% (FCF TTM -291.8m / Enterprise Value 4.77b)
FCF Margin = -8.66% (FCF TTM -291.8m / Revenue TTM 3.37b)
Net Margin = -32.84% (Net Income TTM -1.11b / Revenue TTM 3.37b)
Gross Margin = 56.21% ((Revenue TTM 3.37b - Cost of Revenue TTM 1.48b) / Revenue TTM)
Gross Margin QoQ = 16.53% (prev 11.68%)
Tobins Q-Ratio = 0.86 (Enterprise Value 4.77b / Total Assets 5.55b)
Interest Expense / Debt = 5.26% (Interest Expense 148.0m / Debt 2.81b)
Taxrate = 21.0% (US default 21%)
NOPAT = -699.9m (EBIT -885.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.71 (Total Current Assets 837.2m / Total Current Liabilities 489.4m)
Debt / Equity = 1.44 (Debt 2.81b / totalStockholderEquity, last quarter 1.96b)
 Debt / EBITDA = -3.84 (negative EBITDA) (Net Debt 2.65b / EBITDA -691.2m)
 Debt / FCF = -9.10 (negative FCF - burning cash) (Net Debt 2.65b / FCF TTM -291.8m)
 Total Stockholder Equity = 2.53b (last 4 quarters mean from totalStockholderEquity)
RoA = -18.93% (Net Income -1.11b / Total Assets 5.55b)
RoE = -33.67% (Net Income TTM -1.11b / Total Stockholder Equity 3.29b)
RoCE = -15.32% (EBIT -885.9m / Capital Employed (Equity 3.29b + L.T.Debt 2.49b))
 RoIC = -14.13% (negative operating profit) (NOPAT -699.9m / Invested Capital 4.95b)
 WACC = 6.26% (E(2.12b)/V(4.93b) * Re(9.05%) + D(2.81b)/V(4.93b) * Rd(5.26%) * (1-Tc(0.21)))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -33.33 | Cagr: -0.49%
 [DCF] Fair Price = unknown (Cash Flow -291.8m)
 EPS Correlation: -89.71 | EPS CAGR: -19.93% | SUE: 1.87 | # QB: 1
Revenue Correlation: 98.66 | Revenue CAGR: 6.79% | SUE: 0.39 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.37 | Chg30d=-19.88% | Revisions=-50% | Analysts=13
EPS next Quarter (2026-09-30): EPS=0.48 | Chg30d=-2.09% | Revisions=+0% | Analysts=13
EPS current Year (2026-12-31): EPS=1.50 | Chg30d=+1.88% | Revisions=+54% | GrowthEPS=-24.9% | GrowthRev=+2.9%
EPS next Year (2027-12-31): EPS=1.73 | Chg30d=+3.49% | Revisions=+54% | GrowthEPS=+15.6% | GrowthRev=+5.8%
[Analyst] Revisions Ratio: +54%